NAIC C-2 Longevity Risk RBC Charge: Framework Takes Shape for PRT and Longevity Reinsurance

Tracking every NAIC Longevity Risk (E/A) Subgroup exposure since 2017, the 2026 draft is the first version where the Academy of Actuaries and Subgroup agree on the direction of the ceded longevity charge, which is usually the final step before a field test protocol is published. At the Spring 2026 National Meeting in Indianapolis, the Academy's Longevity Risk Task Force walked the Subgroup through its revised responses on retained and ceded longevity exposure, proposing a scenario-based stress that would sit inside C-2 (insurance risk) rather than being bolted onto C-3. With a year-end 2027 target effective date, a late-April follow-up Subgroup meeting on the calendar, and a companion C-3 field test on the Generator of Economic Scenarios already running in parallel, pension risk transfer (PRT) writers and longevity reinsurers have roughly three quarters to price the new charge into their 2027 capital plans before pre-adoption disclosures are expected to land in 2026 annual statements.

What the Longevity Risk (E/A) Subgroup Is and Why C-2, Not C-3

The Longevity Risk (E/A) Subgroup was originally chartered under the Life Risk-Based Capital (E) Working Group and the Life Actuarial (A) Task Force as a joint body, which is why it carries the (E/A) designation. Its charge is to evaluate whether longevity risk should be recognized explicitly in the U.S. life RBC formula, and if so, how. Historically, U.S. life RBC has treated longevity risk implicitly through the C-2 insurance risk component for annuities in payout, with a flat factor applied to annuity reserves that does not distinguish between immediate annuities, deferred annuities, or group annuity contracts backing a pension risk transfer. The Subgroup's working premise, refined over multiple exposure drafts since 2017, is that the explosive growth of the PRT market and the development of an active longevity reinsurance market have made the implicit treatment inadequate.

The choice to place the new charge inside C-2 rather than C-3 is substantive. C-3 is the interest rate and market risk component, and the ongoing Summer 2026 C-3 field test on the new Generator of Economic Scenarios (GOES) framework is consuming most of the oxygen in the Life RBC Working Group's Spring 2026 agenda. Longevity risk, however, is fundamentally a mortality and behavior risk, not a market risk. It manifests in the actual-versus-expected deaths on a block of in-payment annuitants, and the present value of the resulting cash flow deviation is the quantity the RBC formula needs to protect against. Placing the charge in C-2 keeps the taxonomy clean: interest and equity risk sit in C-3, mortality and longevity risk sit in C-2, asset credit and default risk sit in C-1.

The other reason the C-2 placement matters is covariance. The U.S. life RBC formula uses a square-root covariance adjustment across C-1, C-2, C-3, and C-4 to recognize that not all risks crystallize simultaneously. A new C-2 longevity charge gets the benefit of covariance with C-1 (asset risk) and C-3 (interest rate risk), which materially softens the headline capital impact compared to a standalone add-on. For a PRT writer whose dominant risk is C-3 interest, the covariance offset means a gross longevity charge of, say, $200 million can translate to a net after-covariance impact closer to $140 million to $160 million depending on the company's overall RBC profile.

The Academy Task Force Responses: Retained Versus Ceded

The central technical contribution of the Academy's Longevity Risk Task Force is the separation of retained and ceded longevity exposure into two distinct pieces of the charge, each with its own arithmetic. Under the 2026 draft framework, the C-2 longevity component has three building blocks.

Building Block One: Retained Longevity on Payout Annuities

For annuities in payout that the company has not ceded, the Task Force proposes a scenario-based stress: calculate the present value of annuity cash flows under a deterministic mortality improvement scenario (on the order of an additional 1.5 percent annual improvement layered on top of the valuation basis), compare the stressed PV to the baseline PV, and hold capital equal to a specified percentage of the PV increase. The stress is applied to single premium immediate annuities, group annuity PRT contracts, and the in-payment portion of deferred annuity blocks. The Task Force's current recommendation is a stress severity calibrated to roughly a 1-in-200 longevity outcome over a one-year time horizon, which aligns broadly with the 99.5 percent VaR calibration used elsewhere in the U.S. and international capital frameworks.

Building Block Two: Ceded Longevity Risk

Where the company has ceded longevity exposure through a longevity swap, a longevity reinsurance treaty, or a full PRT cession, the Task Force proposes a reduced charge that reflects counterparty credit exposure rather than direct mortality exposure. The arithmetic here is where the 2026 draft moved most relative to prior exposure versions. Earlier drafts applied the retained-business stress at a flat reduction (often 50 to 70 percent) to ceded positions, which industry commenters argued overstated the residual risk at well-collateralized treaties with investment-grade counterparties. The 2026 draft ties the ceded charge to a combination of counterparty NAIC designation, collateral structure, and recapture trigger terms.

Specifically, a ceded position with a Bermuda-regulated reinsurer posting USD collateral to a Regulation 114 trust carries a lower charge than the same position ceded to an unauthorized reinsurer without collateral. The draft provides a factor table that maps counterparty rating and collateral posture to a ceded-risk factor, which is then applied to the underlying retained stress PV. The effect is that a company ceding 80 percent of its longevity risk to a well-collateralized Bermuda sidecar sees a ceded charge that can be an order of magnitude smaller than the retained equivalent.

Building Block Three: Assumed Longevity Risk

Companies that assume longevity risk (reinsurers and sidecars writing longevity swaps or PRT retrocessions) face the retained-business stress on the assumed exposure, net of any further retrocession. This matters for the small but fast-growing group of U.S.-licensed reinsurers and affiliated offshore entities writing longevity business. The draft framework treats assumed longevity symmetrically to retained direct exposure, which aligns with how the international capital frameworks handle the same question.

The RBC Arithmetic: A Modeled Mid-Size PRT Writer

The clearest way to see what the new charge actually does is to walk it through a specific company profile. Consider a mid-size U.S. life insurer with $10 billion of longevity exposure, roughly half from single premium immediate annuities written directly and half from group annuity PRT transactions closed over the past three years. Assume the company has ceded 60 percent of its PRT exposure to a well-collateralized Bermuda longevity reinsurer and retained 40 percent, and that none of the SPIA block has been ceded. That gives the company $5 billion of retained SPIA exposure plus $2 billion of retained PRT exposure (40 percent of $5 billion), for $7 billion total retained, and $3 billion of ceded PRT.

Retained Stress Calculation

Apply the proposed 1.5 percent additional annual mortality improvement stress to the retained $7 billion. Under a representative U.S. SPIA and PRT cash flow profile with a duration of approximately 11 years, a 1.5 percent additional improvement layered on the 2025 valuation mortality table produces a PV increase of roughly 5.5 to 6.5 percent, or approximately $420 million on $7 billion of reserves. The Task Force's current draft would then apply a capital factor of approximately 35 percent to that PV increase, producing a gross retained longevity charge of about $145 million.

Ceded Component

Apply the stress to the $3 billion of ceded exposure on a gross basis, producing a PV increase of approximately $180 million. The ceded-risk factor for a well-collateralized Bermuda reinsurer in the draft framework is roughly 8 to 12 percent of the equivalent retained factor. At a 10 percent factor, the ceded-component charge is approximately $18 million (10 percent of $180 million ceded stress multiplied by the 35 percent capital factor means the net is closer to $6 million in some draft readings; the precise arithmetic depends on where the factor reduction is applied, but the practical answer is that the ceded piece contributes a small fraction of the retained piece).

Gross and Net Charge

Adding the retained and ceded components yields a gross C-2 longevity charge in the range of $150 million to $155 million for this illustrative mid-size writer. Running this through the covariance formula with the company's existing C-1 and C-3 positions (assume $800 million C-1 and $600 million C-3), the net after-covariance impact on total RBC capital is approximately $100 million to $120 million, or roughly 12 to 15 basis points of the company's total adjusted capital base at a typical capital ratio.

Exposure Component	Reserve Base	Stressed PV Increase	Capital Factor	Gross Charge
Retained SPIA	$5.0B	~$300M	35%	~$105M
Retained PRT	$2.0B	~$120M	35%	~$42M
Ceded PRT (well-collateralized BDA)	$3.0B	~$180M	~3.5% effective	~$6M
Total gross C-2 longevity	$10.0B			~$153M
Net after covariance				~$110M

Two things stand out in the walk. First, the ceded charge is small in absolute terms, which is the intended result of the Task Force's refinement: a well-collateralized cession should not produce a charge anywhere near the retained equivalent. Second, the covariance benefit is meaningful for companies with substantial C-1 or C-3 exposure. Thinly capitalized monoline PRT writers or longevity-only reinsurers with limited asset risk see a smaller covariance offset and therefore a larger net impact per dollar of gross charge.

How This Compares to Solvency II's Longevity Sub-Module

The proposed U.S. C-2 longevity charge lands in a different place on the calibration and design spectrum than the Solvency II longevity sub-module that UK and EU PRT carriers already operate under. Understanding the differences matters for U.S. carriers because the international comparison is the first question investors and rating agencies will ask once the framework is adopted.

Solvency II Calibration

The Solvency II longevity sub-module under the Standard Formula applies a permanent 20 percent reduction to mortality rates across all ages and durations for liabilities where a mortality decrease generates an increase in technical provisions. The 20 percent shock is applied at the best-estimate mortality basis and flows through the standard formula capital calculation. For internal model firms (which includes most large UK PRT writers), the longevity calibration is firm-specific but is required to produce a capital outcome at least consistent with the 99.5 percent one-year VaR standard.

Key Differences

The proposed U.S. C-2 framework differs from Solvency II in four important ways:

Stress definition: Solvency II applies a flat 20 percent mortality reduction, while the U.S. draft applies an additional mortality improvement layered on top of the valuation basis. Mathematically, the two approaches produce similar PV outcomes for medium-duration blocks but diverge for very long-duration books where cumulative improvement effects compound.
Ceded recognition: Solvency II recognizes reinsurance through the risk mitigation rules in Article 209 of the Delegated Regulation, which requires effective risk transfer and collateral requirements that mirror but do not exactly match the U.S. draft factor table.
Capital ratio target: Solvency II targets a 99.5 percent VaR over one year for the SCR. The proposed U.S. charge is calibrated to a similar tail severity but operates within the RBC covariance structure, which makes direct numerical comparison imprecise.
Sub-module scope: Solvency II's longevity sub-module covers only products where a longevity decrease increases reserves, which excludes traditional life insurance. The U.S. draft explicitly scopes C-2 longevity to in-payment annuities and the payout phase of deferred annuities, which is consistent with the Solvency II scope but arrived at by a different route.

How UK PRT Carriers Price Capital

UK bulk annuity writers (Legal & General, Pension Insurance Corporation, Rothesay, Just Group, Aviva, Canada Life, M&G, Scottish Widows, and Royal London) price longevity capital into PRT deal economics through an internal model longevity charge that typically lands at 3 to 5 percent of gross liability PV, measured at the 99.5 percent one-year VaR calibration. This is materially higher than the U.S. C-2 draft translated to an equivalent ratio (the modeled $153 million gross charge on $10 billion of exposure lands at roughly 1.5 percent of liability PV before covariance). The gap reflects a combination of calibration conservatism in internal models, longer UK pension duration, and the more granular mortality basis used by UK writers.

For U.S. PRT writers, the practical takeaway from the UK comparison is that the proposed C-2 charge is not overly punitive relative to international peers. Investors and rating agencies comparing cross-border capital intensity will see the U.S. charge as calibrated conservatively but not excessively, which supports continued capital flow into the U.S. PRT market.

The 2027 Target Effective Date and Pre-Adoption Disclosures

The Subgroup's current working plan is a year-end 2027 effective date for the new C-2 longevity charge, with an exposure draft of the final framework expected in Summer 2026 and a formal adoption vote late in 2026. That timeline is ambitious but achievable given that the Academy and Subgroup now agree on the direction of the ceded charge, which has historically been the gating technical issue. A field test on a voluntary basis may run parallel to the exposure draft comment period, similar to the C-3 GOES field test running this summer, though the Subgroup has not yet committed to a formal field test protocol.

What Carriers Should Prepare in 2026 Annual Statements

Even with a 2027 effective date, carriers with material longevity exposure should plan for two sets of pre-adoption disclosures in their 2026 annual statements and supporting actuarial memoranda.

Sensitivity Disclosures in the Actuarial Opinion and Memorandum

Appointed actuaries preparing the 2026 asset adequacy analysis should consider whether a sensitivity test on the proposed C-2 longevity stress is appropriate under ASOP 22 and the NAIC Actuarial Opinion and Memorandum Regulation. For companies where the draft charge would produce a material change in the RBC ratio, disclosure of the sensitivity in the Regulatory Asset Adequacy Issues Summary (RAAIS) provides regulators with advance visibility into the forthcoming capital impact. The disclosure is voluntary but increasingly expected for companies with concentrated PRT or longevity reinsurance positions.

Forward-Looking Management's Discussion and Analysis

Public life insurers with material PRT exposure should address the forthcoming C-2 charge in Management's Discussion and Analysis (MD&A) disclosures for the 2026 10-K, particularly for carriers where the net capital impact materially affects the capital return program, dividend capacity, or reinvestment capacity. Under SEC Regulation S-K Item 303, MD&A should discuss known trends or uncertainties that are reasonably likely to have a material effect on results of operations or financial condition. A new RBC charge with a known effective date and a modeled capital impact fits cleanly into that standard.

Rating Agency Engagement

AM Best, S&P, and Moody's have all signaled that they intend to incorporate the proposed C-2 longevity charge into their internal capital models ahead of the statutory effective date. Carriers should expect rating agency inquiry letters in Q3 and Q4 2026 requesting carrier-specific modeled impacts under the proposed framework. Having clean, defensible internal estimates ready in Q2 2026 is a practical necessity, not just good hygiene.

What the C-2 Framework Changes for Brookfield-Just Class PRT Deals

The April 1, 2026 close of Brookfield Wealth Solutions' acquisition of Just Group is a useful test case for how the proposed C-2 charge reshapes the economics of the cross-border PRT transaction class. That deal consolidated a UK bulk annuity writer with significant longevity exposure into a Bermuda-domiciled parent structure, with internal reinsurance and affiliated investment management as the central value drivers. The U.S. C-2 charge does not apply to UK-domiciled business, but the deal's archetype (large insurer being acquired by a capital-efficient platform with offshore reinsurance and private credit investment) has analogs in U.S. PRT M&A that do fall within the proposed framework.

Three Economic Effects

First, the ceded-charge calibration favors well-collateralized Bermuda cessions, which preserves the economic logic of the Brookfield-Just structure when applied to U.S. PRT writers. A U.S. domestic PRT writer acquired by a Bermuda platform can cede substantial longevity risk offshore without generating a punitive charge, provided the collateral and counterparty rating requirements are met.

Second, the retained-risk calculation interacts with the asset strategy in a subtle way. The Brookfield-Just class deal thesis depends on investment outperformance, often through private credit, CLOs, and direct lending strategies. The new C-2 charge sits on top of existing C-1 asset risk factors, including the CLO factor track that the NAIC Risk-Based Capital Investment Risk and Evaluation Working Group is recalibrating in parallel. A platform acquiring a U.S. PRT writer therefore faces two simultaneous capital recalibrations: the C-1 asset-side recalibration on its investment strategy, and the new C-2 longevity charge on the liability side. The net capital impact depends on both, and the covariance offset between them reduces the sum relative to a simple addition.

Third, recapture triggers in longevity reinsurance treaties become more valuable under the new framework. Because the ceded-charge factor depends on counterparty rating and collateral posture, a cedant that retains strong recapture rights (for example, on a downgrade of the reinsurer below a specified threshold) effectively caps its tail capital exposure. Treaties written without robust recapture triggers carry a higher effective ceded charge because the reinsurer credit deterioration scenario is not mitigated.

Operational Readiness and Modeling Infrastructure

The proposed C-2 longevity charge requires modeling infrastructure that some PRT writers have not built. Three capabilities matter most.

Granular Payout Annuity Cash Flow Projections

Calculating the PV stress requires projecting annuity cash flows under both the baseline valuation mortality assumption and the stressed assumption, at sufficient granularity to capture age, gender, and spouse survivorship structures. Companies that run PRT cash flows at aggregated cohort levels for reserve purposes may need to refine to policy-level or finer-cohort projection engines. The incremental compute and model validation lift is not trivial for large in-force blocks.

Treaty-Level Ceded Tracking

The ceded-charge factor depends on counterparty attributes (NAIC designation, collateral structure, recapture terms) at the treaty level. Companies with multiple longevity reinsurance treaties and retrocessions need a treaty database that maps each cession to its applicable factor. Carriers that have been tracking cessions at an aggregate or business-line level will need to refine the tracking to treaty specificity.

Integration with RBC Reporting Software

The major RBC reporting software vendors (Moody's AXIS, FIS PathWise, Milliman MG-ALFA, and the in-house systems at several large carriers) will need to add the new C-2 longevity component to their formula engines ahead of the effective date. Vendor release timelines are typically one to two years behind NAIC adoption, which puts pressure on companies to have the vendor roadmap clarified by mid-2026 if they are relying on vendor support rather than in-house RBC formula code.

The Politics of Simultaneous Capital Changes

The proposed C-2 longevity charge is not the only RBC change in flight. The Summer 2026 C-3 field test on the GOES generator, the CLO RBC factor recalibration running through the Risk-Based Capital Investment Risk and Evaluation Working Group, and the ongoing debate over private credit and affiliated investment transparency all converge in the same 2026 to 2027 window. For the industry, the cumulative picture is a once-in-a-decade recalibration of the life RBC formula across C-1, C-2, and C-3 in roughly the same 18-month span.

That convergence creates both risk and opportunity. The risk is that carriers with weak capital positions may face a cliff at the 2027 year-end if multiple charges land simultaneously without transition relief. The opportunity is that regulators, seeing the convergence, may be willing to stage adoptions, provide interim capital relief, or allow dual-basis reporting for a transition period. Industry comment letters on the longevity framework should explicitly address the interaction with the parallel C-1 and C-3 changes, because the Subgroup's framework choices look different viewed in isolation than viewed as one leg of a three-legged capital recalibration.

Why This Matters

The U.S. PRT market closed roughly $50 billion in premium in 2025 and is on pace for another year of double-digit deal-count growth in 2026. The longevity reinsurance market supporting those deals has grown commensurately, with several new Bermuda sidecars and affiliated reinsurers launched in 2024 and 2025 specifically to participate in U.S. and UK longevity risk. A new C-2 RBC charge reshapes the after-capital economics of every in-force dollar of that exposure and every new deal written from 2027 forward.

For appointed actuaries and chief actuaries at PRT writers, the practical calendar is tight. The 2026 Q2 and Q3 modeling cycle should produce a carrier-specific estimate of the gross and net C-2 charge under the current draft, with sensitivities around the retained-risk factor, the ceded-risk counterparty table, and the covariance offset. The 2026 annual statement disclosures should reflect the forward-looking impact where material. The 2027 capital plan and capital return program should incorporate the charge at its expected magnitude.

For pricing actuaries quoting new PRT business in 2026 and 2027, the charge enters the pricing calculation directly. A $500 million group annuity deal that previously carried a capital cost of roughly 3 to 4 percent of premium under the current implicit treatment may carry an additional 50 to 80 basis points under the explicit C-2 charge, which compresses gross margins on fixed-price quotes and forces repricing on deals with loss ratio or experience refund provisions. Plan sponsors have not yet repriced their PRT expectations to reflect this, which creates transitional friction in the deal pipeline through 2027.

For reinsurers and sidecars assuming longevity risk, the draft framework is broadly favorable. The explicit recognition of ceded risk at a lower factor when well-collateralized, combined with the ceded-charge sensitivity to counterparty rating, creates a market incentive for reinsurers to maintain high ratings and robust collateral structures. Reinsurers that can offer that combination should see sustained or growing demand from cedants optimizing their C-2 charge.

The Bottom Line

The 2026 draft is the first version where the Academy and the Subgroup agree on the direction of the ceded-risk charge. In the lifecycle of NAIC RBC changes, that agreement is typically the final technical step before a field test protocol is published and a formal exposure draft is released for comment. The year-end 2027 target effective date is achievable, and the proposed framework is calibrated conservatively but not punitively relative to international peers.

For the PRT market and the longevity reinsurance market, the C-2 charge is not a disruption: it is an explicit recognition of risk that has always been present but implicitly treated. The writers and reinsurers that engage with the framework through the field test and exposure draft phases, model the carrier-specific impact early, and update pricing and capital plans on the Subgroup's calendar will be best positioned when the charge takes effect. Companies that wait for final adoption to start modeling will face a compressed window to recalibrate capital plans, pricing, and treaty economics simultaneously.

From tracking every NAIC Longevity Risk Subgroup exposure since 2017, the signal in the 2026 draft is that the framework has matured past the conceptual debate about whether longevity warrants its own charge and into the technical calibration phase. That phase has historically run 12 to 24 months before adoption at the NAIC. For carriers writing or assuming material longevity risk, the runway is now.